Exelixis (EXEL) cash flow statement

Biotechnology · NASDAQ · Health Care

$68.50 +2.09% Close Nov 17, 2026 Live

TrendArc score 85 of 100 · Health 9.9 · Momentum 8.8 · Moat 4.5 · scored Nov 17, 2026 · How the score works

Free cash flow, fiscal year to December 31, 2025

$876 million

up 30.4% from the year before

Exelixis generated $876 million of free cash flow in the fiscal year to December 2025: $884 million of cash from operations less $8 million of capital spending. That was 37.7% of revenue, against 31.0% the year before. Over the last four quarters, to September 30, 2026, it was $1.2 billion.

What stands out

  • Over the five fiscal years to December 2025 it paid $2.0 billion in net share repurchases, 78% of its free cash flow over the same years.
  • Free cash flow was 37.7% of revenue in the fiscal year to December 2025, the highest of 11 companies in Biotechnology on TrendArc.
  • Free cash flow exceeded net income in each of the last five fiscal years: $2.5 billion against $1.9 billion in total.
  • Diluted shares outstanding fell 11.4% over the five fiscal years to December 2025.

Each sentence is written by a fixed rule from the figures on this page.

Free cash flow and net income, the last 10 fiscal years

-$250M$250M$500M$750M$1.00B2016201720182019202020212022202320242025$209MFree cash flow $876MNet income $783M-$250M$250M$500M$750M$1.00B20172019202120232025Free cash flow $876MNet income $783M

Fiscal years, each labelled by the calendar year it ended in. Every figure is in the statement below.

Where the cash wentFiscal year to December 31, 2025

  1. Cash from operations 884
  2. Capital spending -8
  3. Free cash flow 876
  4. Investments bought and sold, net 390
  5. Net share repurchases -898
  6. Debt and other -103
  7. Net change in cash 265

In millions of US dollars. Outflows are grey, not red: a buyback is not a loss. "Debt and other" closes the gap to the reported change in cash. Buying marketable securities moves cash into short-term investments; the balance sheet shows both.

Cash flow statement, the last 10 fiscal years

In millions of US dollars. Each column is a fiscal year, named by the month it ended; the first column adds up the last four quarters. Cash paid out is a negative number.
Fiscal year toLast 4 quarters
to Sep 2026
Dec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
Operating activities
Net income783521208182231112321690154-70
Depreciation and amortisation53565539191411811
Stock-based pay1101139410610812010557412423
Working capital and other items-6529-353431-22138-323-14257
Cash from operations1,173884700333363401209527416166210
Investing activities
Capital spending-12-8-28-40-28-54-30-13-33-21-2
Businesses bought and sold, net0000000000
Investments bought and sold, net390-51136-38621-101-574-26558-213
Other investing-31-38-123-111-1000000
Cash from investing350-117-27-524-43-131-587-29837-215
Financing activities
Debt issued or repaid, net00000000-186-1
Shares issued less bought back-1,227-898-590-51724242522172228
Dividends paid00000000000
Other financing-71-39-29-23-39-50-10-8-7-11
Cash from financing-970-629-5461-15-251310-17016
Net change in cash265-46-240-16134353-481283212
Free cash flow
Free cash flow1,161876672293335347179514383145209
Free cash flow margin46.5%37.7%31.0%16.0%20.8%24.2%18.1%53.1%44.8%32.0%109.1%
Free cash flow per share$3.11$2.27$0.91$1.03$1.08$0.56$1.63$1.22$0.46$0.83
Free cash flow less stock-based pay76357818722722774458342121186

Shares issued less bought back is the cash from shares sold less the cash paid for shares bought back (negative when more was bought back), and includes tax withheld when employees' shares vest. Working capital and other items is cash from operations less net income, depreciation and amortisation, and stock-based pay (calculated by TrendArc). Company filings as standardised by Tiingo; calculations by TrendArc. Rebuilt nightly.

Exelixis against its peers

CompanyFiscal year toFree cash flowFree cash flow margin
ExelixisEXEL Dec 2025$876M37.7%
RegeneronREGN Dec 2025$4.08B28.4%
Vertex PharmaceuticalsVRTX Dec 2025$3.19B26.6%
IncyteINCY Dec 2025$1.35B26.3%
BiogenBIIB Dec 2025$2.02B20.4%
Alnylam PharmaceuticalsALNY Dec 2025$465M12.5%
ModernaMRNA Dec 2025-$2.08B-106.7%
InsmedINSM Dec 2025-$968M-159.6%
Peer median20.4%

Each company's newest fiscal year; some end in other months. The peers are the stock card's peer group.

Next

Follow Exelixis with a free account.

A watchlist, price alerts and saved chart layouts. No card needed.

Sign up free

No forecast, no recommendation. This page describes Exelixis from published data; it is not advice to buy, sell or hold any security.

Figures as of the close on Nov 17, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.

The TrendArc score, from 0 to 100, combines three pillars measured from published data, Health (business quality over the last twelve months), Momentum (the price against its moving averages, its 52-week high and the market) and Moat (durability over five years), with the share price's long-run trend. It describes the company as it stands today. It is not a forecast or a recommendation.